AstraZeneca Ups Core EPS Guidance Despite Profit Miss

AstraZeneca raised its full-year guidance for core earnings per share and total revenue excluding Covid-19 medicines despite a lower third-quarter profit that missed forecasts. The Anglo-Swedish pharmaceutical giant said Thursday that it expects core earnings per share to increase by a low…#astrazeneca #anglo #swedish
Source: Reuters: Health - Category: Consumer Health News Source Type: news